Lifeline Ductus Arteriosus Stent for Ductal Patency
Ductus Arteriosus Stent
Congenital Abnormalities+3
+ Cardiovascular Diseases
+ Heart Defects, Congenital
Treatment Study
Summary
Study start date: October 1, 2025
Actual date on which the first participant was enrolled.This study is being conducted to evaluate a medical device called the Lifeline Ductus Arteriosus Stent System. The main goal is to see if this stent is safe and effective for patients who need their ductus arteriosus to remain open, which is a critical condition in some heart patients, particularly infants with certain congenital heart defects. The researchers are gathering data to potentially gain approval from the Food and Drug Administration (FDA), which would help make this treatment more widely available and improve care for those with this specific medical need. Participants in the study will receive the Lifeline Ductus Arteriosus Stent as part of their treatment. This stent is a small device that is placed in the ductus arteriosus to keep it open. The study will monitor how well the stent works and any side effects that occur. Although the study does not explicitly mention risks or benefits, typically, such studies aim to ensure that the device is both effective in its function and safe for patients to use.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.35 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Until 6 Months
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Study Objectives
Primary Objectives